Prostate Cancer Drugs Global Market Report 2026

Prostate cancer drugs are medications used for the prevention and treatment of prostate cancer. Prostate cancer is a common type of cancer that occurs due to the uncontrolled growth of cells in the prostate gland in men, which produces the seminal fluid that nourishes and transports sperm. Some potential treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy.

Prostate cancer drugs can be classified into hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a type of prostate cancer that no longer responds to hormone therapy, including newer treatments. The available therapies include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and are used across various settings such as hospitals, clinics, and other healthcare facilities.

Tariffs have increased the cost of imported APIs and specialty oncology drugs used in prostate cancer treatment across multiple therapy classes. These impacts are most pronounced in targeted therapy segments and hospital procurement channels, where pricing sensitivity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on cross border oncology supply chains. Rising tariff related expenses have influenced treatment pricing, reimbursement discussions, and procurement planning in oncology care settings. Conversely, tariffs have encouraged domestic pharmaceutical production, expanded local manufacturing capacity, and improved regional drug availability over the long term.

The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2025 to $20.54 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to aging male population, increased prostate cancer screening, widespread hormone therapy adoption, expansion of oncology clinics, rising cancer awareness.

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growth in targeted and immunotherapy drugs, rising incidence of advanced prostate cancer, increasing treatment personalization, expanding healthcare access, growth in oncology spending. Major trends in the forecast period include rising use of hormonal therapy in early treatment, increased adoption of targeted prostate cancer drugs, growing focus on castration-resistant prostate cancer, expansion of combination therapy approaches, increased hospital-based prostate cancer care.

The growing male geriatric population is anticipated to drive the expansion of the prostate cancer drugs market in the coming years. The male geriatric population refers to men aged 65 and above, who generally face a higher prevalence of age-related health conditions and require specialized medical care. This increase in the aging male population is attributed to better access to healthcare, declining mortality rates, and longer life expectancies globally. The rising number of elderly men fuels demand for prostate cancer drugs by increasing the patient base in need of hormonal therapies, immunotherapies, chemotherapy, and targeted treatments for disease management and improved survival. For example, in February 2025, the World Health Organization, a Switzerland-based international public health organization, reported that global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and above worldwide is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the increasing male geriatric population is driving the growth of the prostate cancer market.

Major companies operating in the prostate cancer drugs market coordinate their efforts in launching new products and securing approvals from federal agencies to maximize market revenues. The drug development and approval process is lengthy and complex, making it crucial for drug sponsors to understand the regulatory requirements and marketing pathways necessary to ensure reasonable assurance of safety and effectiveness. For example, in June 2023, AstraZeneca PLC, a UK-based pharmaceutical company, and Merck & Co. Inc., a US-based pharmaceutical company, announced that the United States Food and Drug Administration (USFDA), a federal agency under the US Department of Health and Human Services, approved LYNPARZA (olaparib) in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). LYNPARZA plus abi/pred showed clinically significant improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) compared to abi/pred alone in patients with BRCAm mCRPC, according to an exploratory subgroup analysis of the Phase 3 PROpel trial, which formed the basis for this approval.

In March 2024, Johnson & Johnson, a US-based pharmaceutical industry company, acquired Ambrx Biopharma Inc. for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to develop targeted oncology therapeutics using Ambrx's proprietary ADC technology, which combines highly specific monoclonal antibodies with potent chemotherapeutic agents. This approach enhances the precision of cancer treatments, minimizing common chemotherapy side effects and transforming the treatment landscape for solid tumors, including prostate cancer. Ambrx Biopharma Inc. is a US-based biotechnology company specializing in the development of innovative therapies, including prostate cancer drugs.

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses prostate cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prostate cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Hormone Sensitive Prostate Cancer; Hormone Refractory Prostate Cancer
• 2) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy
• 3) By End User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer; Locally Advanced Prostate Cancer; Metastatic Prostate Cancer
• 2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC); Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Companies Mentioned: Astellas Pharma Inc.; AstraZeneca PLC; Johnson & Johnson; Sanofi S.A.; Bayer AG; Abbott Laboratories; Pfizer Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Tolmar Inc.; AbbVie Inc.; Siemens Healthineers AG; Genomic Health Inc.; OPKO Health Inc.; Siemens Healthcare GmbH; MDxHealth SA; Myriad Genetics Inc.; Janssen Biotech Inc.; Clovis Oncology Inc.; Merck Sharp & Dohme Corp.; Dendreon Corporation; Ferring Pharmaceuticals Inc.; Ipsen Biopharmaceuticals Inc.; Merck & Co. Inc.; Eli Lilly and Company Inc.; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Novartis AG; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Exelixis Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.